Amy K. Erbe

1.1k total citations
55 papers, 525 citations indexed

About

Amy K. Erbe is a scholar working on Oncology, Immunology and Neurology. According to data from OpenAlex, Amy K. Erbe has authored 55 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 33 papers in Immunology and 18 papers in Neurology. Recurrent topics in Amy K. Erbe's work include Immunotherapy and Immune Responses (20 papers), Neuroblastoma Research and Treatments (18 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Amy K. Erbe is often cited by papers focused on Immunotherapy and Immune Responses (20 papers), Neuroblastoma Research and Treatments (18 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Amy K. Erbe collaborates with scholars based in United States, Canada and Taiwan. Amy K. Erbe's co-authors include Paul M. Sondel, Alexander L. Rakhmilevich, Jacquelyn A. Hank, Zachary S. Morris, Ravi B. Patel, Peter M. Carlson, Stephen D. Gillies, Jen Birstler, Raghava N. Sriramaneni and Lakeesha Carmichael and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Amy K. Erbe

50 papers receiving 518 citations

Peers

Countries citing papers authored by Amy K. Erbe

Since Specialization

Citations

This map shows the geographic impact of Amy K. Erbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy K. Erbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy K. Erbe more than expected).

Fields of papers citing papers by Amy K. Erbe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy K. Erbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy K. Erbe. The network helps show where Amy K. Erbe may publish in the future.

Co-authorship network of co-authors of Amy K. Erbe

This figure shows the co-authorship network connecting the top 25 collaborators of Amy K. Erbe. A scholar is included among the top collaborators of Amy K. Erbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy K. Erbe. Amy K. Erbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Lei Shi, Johnathan Ebben, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Paul D. Bates, Matthew H. Forsberg, John A. Kink, Amy K. Erbe, Christian M. Capitini	2
2	High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years? 2025 ·Journal for ImmunoTherapy of Cancer ·Paul M. Sondel, Alexander L. Rakhmilevich, (unknown), Amy K. Erbe	0
3	Ranking antibody binding epitopes and proteins across samples from whole proteome tiled linear peptides 2024 ·Bioinformatics ·Sean J. McIlwain, (unknown), Amy K. Erbe, Paul M. Sondel, Irene M. Ong	1
4	Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors 2024 ·Frontiers in Oncology ·Zafer Gürel, (unknown), (unknown), (unknown), Amy K. Erbe, Aparna H. Kesarwala, Jing Fan, Randall J. Kimple	2
5	Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination 2023 ·Journal for ImmunoTherapy of Cancer ·Peter M. Carlson, Ravi B. Patel, Jen Birstler, (unknown), (unknown), Amy K. Erbe, Amber M. Bates, Ian R. Marsh, Joseph J. Grudzinski, Reinier Hernandez, Alexander Pieper, (unknown), Alexander L. Rakhmilevich, Jamey P. Weichert, Bryan P. Bednarz, Paul M. Sondel, Zachary S. Morris	9
6	Generation of Novel Immunocompetent Mouse Cell Lines to Model Experimental Metastasis of High-Risk Neuroblastoma 2023 ·Cancers ·(unknown), (unknown), Lisa Schneper, Amy K. Erbe, Paul M. Sondel, Vladimir S. Spiegelman	1
7	Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial 2023 ·Cancer Immunology Immunotherapy ·(unknown), Amy K. Erbe, Jennifer Birstler, KyungMann Kim, Ute Hoch, Sue Currie, (unknown), Danni Yu, Arlene O. Siefker‐Radtke, Nizar M. Tannir, Sara M. Tolaney, Adi Diab, Paul M. Sondel	2
8	NK cells propagate T cell immunity following in situ tumor vaccination 2023 ·Cell Reports ·Won Jong Jin, Justin C. Jagodinsky, (unknown), Paul A. Clark, Cindy Zuleger, Amy K. Erbe, Irene M. Ong, (unknown), (unknown), Tracy J. Berg, Alexander L. Rakhmilevich, KyungMann Kim, Michael A. Newton, Mark R. Albertini, Paul M. Sondel, Zachary S. Morris	8
9	Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist 2023 ·Cancer Immunology Immunotherapy ·Alexander Pieper, (unknown), Mildred Felder, (unknown), (unknown), (unknown), Zachary S. Morris, Amy K. Erbe, Alexander L. Rakhmilevich, Paul M. Sondel	3
10	GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies 2022 ·Journal for ImmunoTherapy of Cancer ·Guillem Pascual‐Pasto, (unknown), Rawan Shraim, (unknown), Amy K. Erbe, Doncho V. Zhelev, (unknown), (unknown), Daniel Martínez, Laura Garcia-Gerique, Dimiter S. Dimitrov, Paul M. Sondel, Kristopher R. Bosse	19
11	Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model 2021 ·Journal for ImmunoTherapy of Cancer ·Peter M. Carlson, (unknown), (unknown), Владимир Субботин, (unknown), Ravi B. Patel, Jen Birstler, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Zachary S. Morris, Amy K. Erbe, Paul M. Sondel	14
12	Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice 2021 ·Journal for ImmunoTherapy of Cancer ·Alexander Pieper, Alexander L. Rakhmilevich, (unknown), Ravi B. Patel, Jen Birstler, Won Jong Jin, Peter M. Carlson, Deborah H. Charych, Jacquelyn A. Hank, Amy K. Erbe, Willem W. Overwijk, Zachary S. Morris, Paul M. Sondel	29
13	Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2 2020 ·Clinical Cancer Research ·Richard K. Yang, Igor B. Kuznetsov, Erik A. Ranheim, Jun S. Wei, Sivasish Sindiri, Berkley E. Gryder, Vineela Gangalapudi, Young Song, (unknown), Jacquelyn A. Hank, Cindy Zuleger, Amy K. Erbe, Zachary S. Morris, (unknown), KyungMann Kim, Mark R. Albertini, (unknown), Paul M. Sondel	17
14	In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response 2020 ·Frontiers in Immunology ·Claire Baniel, (unknown), (unknown), (unknown), (unknown), Peter M. Carlson, Won Jong Jin, Ravi B. Patel, Raghava N. Sriramaneni, Stephen D. Gillies, Amy K. Erbe, (unknown), Alexander Pieper, Alexander L. Rakhmilevich, Paul M. Sondel, Zachary S. Morris	12
15	Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition 2019 ·Journal for ImmunoTherapy of Cancer ·(unknown), Amy K. Erbe, (unknown), (unknown), Peter M. Carlson, (unknown), (unknown), Ashley Stuckwisch, Xing Wang, Stephen D. Gillies, Ravi B. Patel, Alvin Farrel, Jo Lynne Rokita, John M. Maris, Jacquelyn A. Hank, Zachary S. Morris, Alexander L. Rakhmilevich, Paul M. Sondel	53
16	Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites 2018 ·Cancer Immunology Research ·Zachary S. Morris, (unknown), Lauryn R. Werner, Peter M. Carlson, (unknown), Jasdeep S. Kler, (unknown), (unknown), Raghava N. Sriramaneni, Lakeesha Carmichael, Hans Loibner, Stephen D. Gillies, Alan J. Korman, Amy K. Erbe, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel	54
17	Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma 2017 ·Radiotherapy and Oncology ·Lauryn R. Werner, Jasdeep S. Kler, (unknown), (unknown), (unknown), (unknown), Joseph G. Kern, (unknown), Amy K. Erbe, Ravi B. Patel, Raghava N. Sriramaneni, Paul M. Harari, Zachary S. Morris	20
18	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma 2016 ·Clinical Cancer Research ·Amy K. Erbe, Wei Wang, Jacob L. Goldberg, (unknown), KyungMann Kim, Lakeesha Carmichael, (unknown), Eneida A. Mendonça, (unknown), Jacquelyn A. Hank, Su–Chun Cheng, Sabina Signoretti, Michael B. Atkins, (unknown), James W. Mier, David J. Panka, David F. McDermott, Paul M. Sondel	12
19	Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells 2016 ·Methods in molecular biology ·Amy K. Erbe, Wei Wang, (unknown), Jacquelyn A. Hank, Paul M. Sondel	7
20	Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure 2009 ·Environmental and Molecular Mutagenesis ·(unknown), Amy K. Erbe, (unknown), Mark A. Pershouse	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact